Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not FDA ...
Jan. 17, 2020 — A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. The ...
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce toxicity, according to Amir Ali, PharmD, BCOP. Tailoring the duration of ...